Side-by-side · Research reference
MazdutidevsTestagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED19/62 cited
BAnimal-MechanisticHUMAN-REVIEWED11/41 cited
Mazdutide
GLP-1/Glucagon Dual Agonist · Oxyntomodulin Analogue · Phase 3
SQ · Abdomen · Once WeeklyJi 2026
Testagen
Bioregulator Peptide · Khavinson School
SQ · Abdomen · Cyclical
01Mechanism of Action
Parameter
Mazdutide
Testagen
Primary target
GLP-1 receptor and glucagon receptorAbdul 2026Elmendorf 2026
Testicular tissue; proposed nuclear DNA interaction
Pathway
Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesisElmendorf 2026Abulehia 2026
Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011
Downstream effect
Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D
Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011
Feedback intact?
Yes — physiological receptor-mediated signaling preserved
Unknown — no HPG axis data
Origin
Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity
Khavinson bioregulator school — isolated from testicular tissue peptide fractions
Antibody development
—
—
02Dosage Protocols
Parameter
Mazdutide
Testagen
Phase 2 studied dose
—
Dose escalation
3 mg → 6 mg → 9 mg (titration schedule in trials)
Gradual escalation to minimize GI side effects.
—
Evidence basis
Animal mechanistic / in vitro onlyFedoreyeva 2011
Duration (trials)
24–48 weeks
—
Population
Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities
—
Typical protocol (anecdotal)
—
100–200 mcg / day
No published human dosing studies; derived from Russian bioregulator practice.
Cycle length
—
10–20 days on, 10–14 days off
Bioregulator tradition uses pulsed cycles; no controlled data.
Reconstitution
—
Sterile water or bacteriostatic saline
Half-life
—
Unknown — likely minutes (short peptide)
03Metabolic / Fat Loss Evidence
Parameter
Mazdutide
Testagen
Percentage body weight loss
12.4% (pooled meta-analysis, 9 mg dose)
95% CI: -16.15% to -8.68%, random-effects model.Azam 2026
—
Responder rate (≥10% loss)
Not explicitly reported in available abstracts
—
Visceral fat
Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts)
—
Glycemic improvement
HbA1c reduction in T2D cohort (Phase 3 DREAMS-3)
—
Key publications
Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026
—
04Side Effects & Safety
Parameter
Mazdutide
Testagen
Gastrointestinal symptoms
Nausea, vomiting, diarrhea (most common, GLP-1 effect)
—
Injection site reactions
Erythema, pruritus, local discomfort
Erythema, mild irritation (potential)
Hypoglycemia
Low risk in non-diabetic cohort; monitor in T2D with insulin or sulfonylureas
—
Cardiovascular effects
Increased heart rate (glucagon effect, transient)
—
Pancreatitis risk
Theoretical (incretin class effect); monitor amylase/lipase if abdominal pain
—
Thyroid C-cell tumors
Black box warning for GLP-1 class (rodent data); human relevance unclear
—
Gallbladder disease
Cholelithiasis, cholecystitis (rapid weight loss effect)
—
Tolerability
Generally well-tolerated; GI effects diminish with dose titration
—
Systemic effects
—
Unknown — no human safety data
Hormonal impact
—
No published data on testosterone, LH, FSH effects
Long-term safety
—
Unknown — no long-term studies
Absolute Contraindications
Mazdutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- ·Hypersensitivity to mazdutide or excipients
- ·Pregnancy
Testagen
- ·Active testicular malignancy
Relative Contraindications
Mazdutide
- ·History of pancreatitis
- ·Severe gastroparesis or GI motility disorders
- ·Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
- ·Renal impairment (limited data, use with caution)
Testagen
- ·Hormone-sensitive cancers (no data; theoretical caution)
- ·Pregnant or breastfeeding (no data)
05Administration Protocol
Parameter
Mazdutide
Testagen
1. Preparation
Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
2. Injection site
Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
3. Timing
Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
4. Storage
Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
5. Needle technique
Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.